Table 1.
Clinicobiological characteristics of the MCL patients in the validation cohort according to the L-MCL16 prediction
| Variable | Total | L-MCL16 prediction | P value (cMCL vs nnMCL) | ||
|---|---|---|---|---|---|
| cMCL | nnMCL | Undetermined | |||
| Number of cases (%) | 70 | 39 (56) | 26 (37) | 5 (7) | |
| Clinical data (at diagnosis) | |||||
| Male/female, n | 40/30 | 24/15 | 15/11 | 1/4 | .8 |
| Nodal presentation, n (%) | 28/67 (42) | 24/39 (62) | 4/24 (17) | 0/4 (0) | .001 |
| Splenomegaly, n (%) | 33/61 (54) | 21/38 (55) | 8/19 (42) | 4/4 (100) | .408 |
| LDH (>ULN), n (%) | 11/47 (23) | 11/30 (37) | 0/15 (0) | 0/2 (0) | .008 |
| MIPI high risk, n (%) | 21/40 (52) | 16/26 (62) | 5/13 (38) | 0/1 (0) | .196 |
| ECOG (≥2), n (%) | 6/40 (15) | 6/25 (24) | 0/14 (0) | 0/1 (0) | .071 |
| Lymphocytosis (L/mm3), median (range) | 9 000 (1 200-236 000) | 9 100 (1 200-149 700) | 9 050 (1 930-236 000) | 5750 (3800-7700) | .936 |
| Pathological and molecular data (at sampling) | |||||
| Mean CCND1 expression | 14.3 | 14.5 | 13.9 | 14.7 | .029 |
| Range CCND1 expression | 11.8-17.4 | 12.6-17.4 | 11.8-16.3 | 11.8-17.4 | |
| IGHV (<97%), n (%) | 27/68 (40) | 5/39 (13) | 20/24 (83) | 2/5 (40) | <.001 |
| 17p/TP53 alteration, n (%) | 24/68 (35) | 14/39 (36) | 9/24 (38) | 1/5 (20) | 1 |
| 9p/CDKN2A deletion, n (%) | 15/68 (22) | 13/39 (33) | 0/24 (0) | 2/5 (40) | .001 |
| 11q deletion, n (%) | 20/68 (29) | 17/39 (44) | 0/24 (0) | 3/5 (60) | <.001 |
| CNA, median (range) | 6.5 (0-52) | 10 (1-43) | 1 (0-45) | 12 (0-52) | <.001 |
| Treatment at diagnosis, n (%)* | <.001 | ||||
| High-dose therapy | 10/67 (15) | 8/38 (21) | 1/24 (4) | 1/5 (20) | |
| Immunochemotherapy | 13/67 (19) | 12/38 (32) | 1/24 (4) | 0/5 (0) | |
| Low-dose chemotherapy | 9/67 (13) | 8/38 (21) | 1/24 (4) | 0/5 (0) | |
| Observation | 35/67 (52) | 10/38 (26) | 21/24 (88)† | 4/5 (80) | |
| Follow-up data | |||||
| Median follow-up, mo | 43 | 35 | 88 | 30 | .019 |
| Mean time from diagnosis to sample (range), mo | 16.6 (0-185) | 2.8 (0-36) | 36 (0-185) | 22.8 (0-92) | .002 |
| Dead patients, n (%) | 24/70 (34) | 16/39 (41) | 7/26 (27) | 1/5 (20) | .296 |
| Treated at 3 y from diagnosis, % (95% CI) | 65 (51-75) | 88 (70-96) | 31 (9-48) | 47 (0-79) | <.001 |
| Treated at 3 y from sampling, % (95% CI) | 71 (57-80) | 89 (73-96) | 44 (19-62) | 47 (0-79) | <.001 |
| 3-y OS, diagnosis, % (95% CI) | 78 (69-89) | 69 (55-86) | 92 (81-100) | 80 (52-100) | .006 |
| 3-y OS, sampling, % (95% CI) | 72 (61-85) | 68 (53-86) | 79 (62-100) | 80 (52-100) | .379 |
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; MIPI, mantle cell lymphoma International Prognostic Index; ULN, upper level of normal.
*
High-dose therapy includes cytarabine-based immunochemotherapy and/or autologous stem cell transplantation, immunochemotherapy includes rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)–like regimens, and low-dose therapy includes alkylating agents alone or in combination.
†
Two patients underwent splenectomy.